You are here

Promising Research into New Targeted Therapies From the 2014 ASCO Annual Meeting

May 31, 2014

·
Amber Bauer, ASCO staff

The 2014 ASCO Annual Meeting continues with more than 25,000 cancer specialists from around the world discussing research that affects cancer care and treatment. Today, positive results from four clinical trials looking into new targeted drugs for advanced ovarian, lung, and thyroid cancers and chronic lymphocytic leukemia were announced. These results suggest new ways to slow cancer growth and lengthen the lives of people whose cancer comes back after treatment or whose cancer becomes resistant to the available treatments.

"Cancer relapses and treatment resistance have always been among the most daunting challenges in cancer care," said Gregory Masters, MD, FACP, a member of ASCO’s Cancer Communications Committee and a medical oncologist at the Helen F. Graham Cancer Center in Newark, DE. "The good news is that genomic medicine is helping to overcome these challenges by revealing new ways to target a cancer cell’s inner workings.”

In this podcast, Dr. Masters provides an overview of the results of these important studies that could lead to new treatment options for patients who have had none, or for whom the side effects of current drugs outweighed their benefits.

Policies and Guidelines:

Contact Us:

Cancer.Net provides timely, comprehensive, oncologist-approved information from the American Society of Clinical Oncology (ASCO), with support from the Conquer Cancer Foundation. Cancer.Net brings the expertise and resources of ASCO to people living with cancer and those who care for and about them to help patients and families make informed health care decisions.